Omalizumab and allergen immunotherapy for respiratory allergies: A mini-review from the Allergen-Immunotherapy Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP)
Allergol. immunopatol
; 50(6): 47-52, 01 nov. 2022. tab
Artigo
em Inglês
| IBECS
| ID: ibc-211523
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Although currently approved to treat severe asthma and chronic spontaneous urticaria, omalizumab has also been an effective and safe add-on treatment for other allergic diseases. Namely, omalizumab has been proposed to be used as add-on therapy in patients with allergic rhinitis and asthma and undergoing specific allergen immunotherapy (AIT). AIT is the only treatment that modifies the natural history of IgE-mediated diseases. This brief review summarizes the available evidence and controversies on the efficacy and safety of omalizumab combined with specific AIT (AU)
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Asma
/
Alérgenos
/
Dessensibilização Imunológica
/
Antiasmáticos
/
Antialérgicos
/
Rinite Alérgica
/
Omalizumab
Limite:
Humanos
Idioma:
Inglês
Revista:
Allergol. immunopatol
Ano de publicação:
2022
Tipo de documento:
Artigo
Instituição/País de afiliação:
ASST-Rhodense/Italy
/
Azienza Ospedaliera Universitaria Policlinico Giovanni XXIII/Italy
/
Casa di cura Villa Montallegro/Italy
/
Department of Pediatrics, Allergy Unit, University of Messina/Italy
/
Department of Pediatrics, Sapienza University of Rome/Italy
/
Istituto Giannina Gaslini/Italy
/
National Research Council/Italy
/
University of Pavia/Italy